More than half of head and neck cancers in Indonesia originate from a site that often goes unnoticed: the nasopharynx, the cavity located behind the nose and throat. At Dr. Sardjito General Hospital in Yogyakarta, dozens of frozen tissue samples from patients with Epstein-Barr virus (EBV)-infected nasopharyngeal cancer became the subject of research that offers new insights into how tumors manipulate their own immune environment. Who conducted the research? drg. Iffah Mardhiyah, M.Biomed, from the Faculty of Dentistry, Universitas Gadjah Mada, together with a multidisciplinary team from various faculties at UGM and other institutions. What did they find? The pro-inflammatory cytokine TNFα, a substance that should serve as the body's alarm signal against infection, was positively correlated with cells that help tumors evade immune attacks. When was the study published? In 2021, in the Asian Pacific Journal of Cancer Prevention. These findings are important because they provide a clearer picture of why nasopharyngeal carcinoma (NPC) is so difficult to eradicate.
Nasopharyngeal carcinoma is a cancer with unique characteristics. In Southeast Asia, including Indonesia, nearly 98% of cases are closely associated with EBV infection. The virus does not act aggressively. Instead, it persists in nasopharyngeal epithelial cells, remains hidden in a latent state, and gradually drives normal cells toward malignancy.
One of the virus's major products is EBER (Epstein-Barr virus-encoded RNA), an RNA molecule found in almost all EBV-infected cells and remaining stable even after being released into the surrounding cellular environment. EBER is known to trigger an immune response through Toll-like receptor 3 (TLR3), an innate immune “sensor” that detects the presence of foreign RNA and stimulates the production of inflammatory cytokines.
The research team posed a simple yet crucial question: does this EBER-TLR3 pathway control the composition of immune cells within nasopharyngeal tumors?
The researchers used 23 FFPE (formalin-fixed paraffin-embedded) tissue samples from EBV-infected NPC patients at Dr. Sardjito General Hospital, collected before the patients received any treatment. The expression of TLR3, TNFα, and IL6 was analyzed using immunofluorescence, while the distribution of two key immune cell types—M2 macrophages and regulatory T cells (Tregs)—was examined using immunohistochemistry.
The results were surprising. All EBER-positive samples showed TLR3 expression. However, TNFα intensity was twice as high as that of IL6. More interestingly, TNFα was positively correlated with the distribution of M2 macrophages (r = 0.137) and Tregs (r = 0.129). In other words, the higher the TNFα level, the greater the presence of immunosuppressive cells in the tumor microenvironment.
M2 macrophages and Tregs are two key players in the tumor's “camouflage” strategy. M2 macrophages are not the type of macrophages that attack tumors; instead, they support tumor growth. Tregs, meanwhile, suppress the activity of other immune cells, preventing them from attacking cancer cells. Together, they create a tumor microenvironment that is conducive to NPC progression.
“TNFα was positively correlated with the distribution of M2 macrophages and Tregs, although this was largely mediated through mechanisms different from the EBER-TLR3 interaction.” — Main conclusion of the study by Iffah Mardhiyah et al., Asian Pacific Journal of Cancer Prevention, 2021
A contradictory finding also emerged. TLR3 was negatively correlated with TNFα (r = -0.303), contrary to previous theories suggesting that the EBER-TLR3 interaction should increase TNFα production. This suggests that EBER may also be capable of suppressing some innate immune signaling, including through its binding to PKR (RNA-dependent protein kinase), thereby inhibiting interferon-mediated antiviral effects.
Meanwhile, the positive correlation between TLR3 and IL6 (r = 0.129) is consistent with previous findings: IL6 acts as an activator of the STAT3 pathway, which accelerates the growth of EBV-infected nasopharyngeal cells while increasing the expression of MMP-2 and MMP-9, enzymes that facilitate cancer cell invasion and migration.
Most of the samples (56.52%) showed low M2 macrophage scores, whereas Treg distribution was more frequently classified as high (52.17%). The combination of low M2 levels and high Treg levels suggests that immunosuppression in NPC does not operate through a single pathway, but rather involves various other cytokines, such as TGF-β, IL-10, IL-4, and IL-13, which were not measured in this study.
This research is more than a molecular mapping study. It opens new avenues for understanding why NPC, despite appearing highly inflamed, can successfully evade immune attacks. If TNFα, a cytokine commonly associated with the body's defense against infection, also contributes to the presence of immune-suppressing cells, then therapies targeting only a single cytokine pathway may not be sufficient.
The researchers also emphasized that understanding M2 macrophages and Tregs could potentially lead to their use as prognostic markers or even as new therapeutic targets for NPC. Tregs, for example, have been identified as an independent prognostic factor for overall survival in patients with NPC.
The research team acknowledged several limitations: the small sample size, the fact that all samples came from patients with advanced-stage disease (stages III and IV), and the lack of patient survival data. However, these limitations also help clarify the direction of future research. The tumor microenvironment is far more complex than previously imagined, and the small virus known as EBV appears to have become remarkably adept at manipulating it.
Authors: drg. Achmad Zam Zam Aghasy, M.Kes. & Annisa Dwi Noviyanti
Photo: Flickr
Source DOI: https://doi.org/10.31557/APJCP.2021.22.8.2363